BR112023001734A2 - Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação - Google Patents

Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação

Info

Publication number
BR112023001734A2
BR112023001734A2 BR112023001734A BR112023001734A BR112023001734A2 BR 112023001734 A2 BR112023001734 A2 BR 112023001734A2 BR 112023001734 A BR112023001734 A BR 112023001734A BR 112023001734 A BR112023001734 A BR 112023001734A BR 112023001734 A2 BR112023001734 A2 BR 112023001734A2
Authority
BR
Brazil
Prior art keywords
formulations
articles
manufacture
methods
autoinjectors
Prior art date
Application number
BR112023001734A
Other languages
English (en)
Portuguese (pt)
Inventor
Pulley Jennifer
Tao Tang Meina
Tole Swati
Tyrrell Helen
Abouhossein Mariam
Amarchinta Hemanth
Boruvka Audrey
Ting Ding Han
L Flores Heather
Scott Giese Glen
Ravanello Renato
Zhang Wenhui
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of BR112023001734A2 publication Critical patent/BR112023001734A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112023001734A 2020-07-31 2021-07-29 Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação BR112023001734A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063059427P 2020-07-31 2020-07-31
PCT/US2021/043690 WO2022026699A1 (fr) 2020-07-31 2021-07-29 Formulations d'anticorps anti-intégrine bêta7 et dispositifs

Publications (1)

Publication Number Publication Date
BR112023001734A2 true BR112023001734A2 (pt) 2023-02-28

Family

ID=77693570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001734A BR112023001734A2 (pt) 2020-07-31 2021-07-29 Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação

Country Status (11)

Country Link
EP (1) EP4188958A1 (fr)
JP (1) JP2023536158A (fr)
KR (1) KR20230041071A (fr)
AR (1) AR123085A1 (fr)
AU (1) AU2021316017A1 (fr)
BR (1) BR112023001734A2 (fr)
CA (1) CA3190109A1 (fr)
IL (1) IL300133A (fr)
MX (1) MX2023001157A (fr)
TW (1) TW202222832A (fr)
WO (1) WO2022026699A1 (fr)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (fr) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2?
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
DK1324776T4 (en) 2000-10-12 2018-05-28 Genentech Inc CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
RS57636B1 (sr) 2004-09-03 2018-11-30 Genentech Inc Humanizovani anti-beta7 antagonisti i njihova upotreba
SI2279004T1 (sl) 2008-05-16 2015-05-29 F. Hoffmann-La Roche Ag Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrina
KR20110128333A (ko) 2009-03-06 2011-11-29 제넨테크, 인크. 항체 제제
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
CA2839493C (fr) 2011-06-17 2016-02-09 Shl Group Ab Dispositif d'injection
US9132236B2 (en) 2011-06-17 2015-09-15 Shl Group Ab Injection device
CN105143876B (zh) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
CN113604543A (zh) 2014-03-27 2021-11-05 豪夫迈·罗氏有限公司 用于诊断和治疗炎症性肠病的方法
EP3262072A1 (fr) * 2015-02-26 2018-01-03 F. Hoffmann-La Roche AG Antagonistes d'intégrine bêta7 et procédés de traitement de la maladie de crohn
WO2019246455A1 (fr) * 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine

Also Published As

Publication number Publication date
EP4188958A1 (fr) 2023-06-07
KR20230041071A (ko) 2023-03-23
IL300133A (en) 2023-03-01
AR123085A1 (es) 2022-10-26
MX2023001157A (es) 2023-02-22
JP2023536158A (ja) 2023-08-23
TW202222832A (zh) 2022-06-16
CA3190109A1 (fr) 2022-02-03
WO2022026699A1 (fr) 2022-02-03
AU2021316017A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
CY1123586T1 (el) Υποδορια σκευασματα αντισωματος her2
CY1123211T1 (el) Meθοδoi γia th θepaπeytikh antimetωπισh ή thn προληψη thς hmikpaniaς
BR112019022972A2 (pt) Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2018002099A (es) Compuestos y métodos para la administración transmembranal de moléculas.
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
BR112014021101A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
BR112014016672A2 (pt) compostos de carbamato e sua preparação e uso
BR112016026811A2 (pt) formulação de anticorpo
SI2691112T1 (en) STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
MX2023009205A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
JOP20220030A1 (ar) صيغ مضادة لـ c5 عالية التركيز
BR112022012514A2 (pt) Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
EP3541943A4 (fr) Micro-organisme pour administrer un médicament pour le traitement d'une maladie gastro-intestinale, qui exprime et sécrète la protéine p8, et composition pharmaceutique comprenant ce micro-organisme destinée à la prévention ou au traitement d'une maladie gastro-intestinale
BR112022012064A2 (pt) Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico
BR112023001734A2 (pt) Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação